The Center for American Principles issues Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients.
CAP stated “We appreciate the opportunity to provide input on the Department’s Section 232 investigation into the national security implications of pharmaceutical imports and their components.
As professionals with longstanding experience in trade, innovation, and biopharmaceutical policy, we support efforts to bolster America’s domestic production capacity in critical sectors, including medicines.
However, we caution against the use of tariffs on pharmaceutical imports as a tool to achieve that goal—particularly when applied to inputs from reliable allies such as Europe and Japan. Our trade relationship with these allies doesn’t risk national security, unlike the nation’s unhealthy dependence on Chinese imports. Instead, tariffs would merely increase the cost of the $128 billion and $6.3 billion in medicines and pharmaceutical ingredients that we import from Europe and Japan, respectively”.